← Compound index
COMPOUND RECORD / ACTOVEGIN

ActoveginАктовегин

A deproteinized calf-blood hemoderivative, a mixture of low-molecular-weight constituents obtained after protein removal. Human trials have examined diabetic neuropathy and cognitive impairment after stroke.

CognitionRecovery
Source linked

What the studies found

Review of earlier studies · 2022

Actovegin in the management of patients after ischemic stroke: A systematic review.

The review found uncertain benefit and no consistent evidence of improved survival, disability, daily activities or quality of life. It flagged potential harm and called for better trials.

Study notes · methods, sources and limitations

Participants or model Five controlled studies after ischemic stroke; one randomized trial and four observational studies

Important limitations

  • Heterogeneous evidence precluded meta-analysis. This review includes ARTEMIDA and is not an independent additional trial.

PloS one · Journal publication

Original source or citation ↗

Study results and tables ↗

Randomized study in people · 2017

ARTEMIDA Trial (A Randomized Trial of Efficacy, 12 Months International Double-Blind Actovegin): A Randomized Controlled Trial to Assess the Efficacy of Actovegin in Poststroke Cognitive Impairment.

ADAS-cog+ change at month 6
−6.8 Actovegin versus −4.6 placebo
Estimated treatment difference
−2.3 points; 95% CI −3.9 to −0.7p=0.005
Recurrent ischemic stroke
More frequent with Actovegin, not statistically significantEvent counts absent from abstract

The trial reported a cognitive-scale benefit at six months. Recurrent ischemic stroke was numerically more frequent with Actovegin, without a statistically significant difference.

Study notes · methods, sources and limitations

Participants or model 503 patients aged 60 or older after ischemic stroke; ARTEMIDA

Design ARTEMIDA: 503 patients age ≥60, MoCA≤25, randomized within one week of stroke: Actovegin 248 versus placebo 255. Up to twenty IV infusions 2,000 mg/day, then oral 1,200 mg/day for six months; follow-up 12 months.

Important limitations

  • Clinical importance and replication remain unresolved. The safety imbalance cannot establish causation or be dismissed as proof of safety. Disease-specific results do not establish healthy-person enhancement.
  • Adjusted treatment difference is retained as −2.3 rather than replacing it with subtraction of the rounded means.

Stroke · Journal publication

Original source or citation ↗

Study results and tables ↗

Randomized study in people · 2009

Treatment of symptomatic polyneuropathy with actovegin in type 2 diabetic patients.

TSS exposure-adjusted difference
−0.56 points; 95% CI −0.85 to −0.27p=0.0003
TSS baseline-to-day-160 difference
−0.86 points; 95% CI −1.22 to −0.50p<0.0001
Vibration threshold, exposure-adjusted
3% decrease; 95% CI 0–6%p=0.084

Neuropathic symptoms improved versus placebo. The vibration-threshold coprimary analysis over time did not reach statistical significance, although the final-visit comparison did.

More reported outcomes
Vibration threshold at day 160
5% decrease; 95% CI 1–9%p=0.017
NIS-LL sensory function
−0.25; 95% CI −0.46 to −0.04p=0.021
Adverse-event incidence
No between-group difference reported
Study notes · methods, sources and limitations

Participants or model 567 treated participants with type 2 diabetes and symptomatic polyneuropathy

Design 567 diabetic-neuropathy patients: Actovegin 281 versus placebo 286. Twenty IV infusions 2,000 mg/day, then oral 1,800 mg/day for 140 days; total 160 days.

Important limitations

  • Endpoint timing matters; these findings do not establish general nerve regeneration or benefit in healthy people. No difference in adverse-event incidence was reported during this trial.
  • The nonsignificant exposure-adjusted vibration endpoint is preserved alongside the significant end-of-study result.

Diabetes care · Journal publication

Original source or citation ↗

Study results and tables ↗
01 / OVERVIEW

About Actovegin

Names in this research collection

Aktovegin

Identity / background source ↗

Research background

Clinical research in diabetic polyneuropathy and post-stroke cognitive impairment. Proposed metabolic effects do not establish protection from hypoxia, enhanced performance or general tissue regeneration.

Compound class
Deproteinized blood-derived preparation
Research collection
Related nootropics & combinations · editorial grouping
Institutions in linked studies
See individual study records
Source review
Review dates and the material assessed are listed with each publication below.
02 / HOW TO READ THE RESEARCH

Understanding the evidence

Human research

Two randomized trials and a stroke systematic review linked below

Study methods

Mixed endpoints; statistical and clinical significance distinguished

Independent replication

Stroke review reuses ARTEMIDA; independent confirmation remains needed

Source access

Indexed abstracts with links to original publications

Safety evidence

Stroke safety imbalance and uncertain benefit require attention; long-term safety not established here

Open a topic for the evidence assessment.

More findings, background and history

Stroke research matrix ↗ — compare human stroke outcomes, experimental findings, safety and adjacent cerebral-ischemia research.

What remains unclear

Group assignment, comparators, planned outcomes, effect estimates, adverse events and possible participant overlap are key limits to interpreting the studies.

Human reports are linked; their presence does not establish effectiveness. Several publications can describe the same participants.

Browse original study records ↗
PATENT RESEARCH / COLLECTION UPDATED 7 NOVEMBER 2026

Patents and claimed inventions

These 1 grouped records distinguish claimed molecules, uses, formulations and related chemistry. Patent disclosure does not establish clinical benefit or approval.

2015 · EA021189B1 · Actovegin: diabetic neuropathy useUse · −5.5 ± 2.6 versus −4.7 ± 2.9; adjusted difference −0.86

Reported findings

Symptom scores favored Actovegin, while some neuropathy and quality-of-life endpoints were neutral. The patent is not independent replication of the journal trial.

Total Symptom Score: end-to-baseline change
−5.5 ± 2.6 versus −4.7 ± 2.9; adjusted difference −0.86End of studyActovegin versus placebo
Time-averaged vibration threshold
Ratio 0.97During treatmentActovegin versus placebo
All reported results, comparisons and limitations →

Use. The patent concerns a deproteinized hemoderivative and diabetic-neuropathy treatment, with clinical material in the disclosure.

Related trial publications and patent descriptions must not be counted as independent clinical replications.

Publication
EA021189B1 ↗ · 2015-04-30
Earliest priority / filing
2008-09-29 / 2009-09-29
Original applicant / assignee
Такеда Австрия Гмбх
Indexed status
Not shown; official status unverified · checked 2026-11-06
Patent family
41345991 · family publications are related filings, not independent studies.
Original title, inventors and related publications

Method for prevention and treatment of diabetic peripheral neuropathy by a deproteinised hemoderivative

Inventors: Лусине Моусесьян.

EA021189B1 · EP2340026B1 · KR20110067054A · CN102264375A · GEP20135901B · WO2010034315A1

Original patent PDF ↗

Read source review →

Status is an indexed snapshot, not an official legal assessment. Search the patent collection and read the method →

03 / SOURCE RECORDS

Findings by study

Explore related research ↗

Experiment described in a patent · 2015

Actovegin: diabetic neuropathy use — EA021189B1

Symptom scores favored Actovegin, while some neuropathy and quality-of-life endpoints were neutral. The patent is not independent replication of the journal trial.

Total Symptom Score: end-to-baseline change · −5.5 ± 2.6 versus −4.7 ± 2.9; adjusted difference −0.86 · Actovegin versus placebo · End of study · 95% CI −1.22 to −0.50; p<0.0001

Study notes and original source
2015Patent / reported experimentsFull text available

Actovegin: diabetic neuropathy use — EA021189B1

Patent-defined substance or composition · Patent publication

Format: Original patent text and indexed metadata · Reviewed: Claims, selected reported findings and limitations reviewed; supporting experiments not comprehensively appraised.

Лусине Моусесьян · EA021189B1 · patent family 41345991

Symptom scores favored Actovegin, while some neuropathy and quality-of-life endpoints were neutral. The patent is not independent replication of the journal trial.

Results and tables

Reported patent results

Reported findings

Symptom scores favored Actovegin, while some neuropathy and quality-of-life endpoints were neutral. The patent is not independent replication of the journal trial.

Patent disclosure of the published Actovegin diabetic-neuropathy program: 569 randomized; treatment/ITT population 281 active and 286 placebo.

Population or model Patent disclosure of the published Actovegin diabetic-neuropathy program: 569 randomized; treatment/ITT population 281 active and 286 placebo.

Results · Description: trial population and Tables 5–9, 13, 21 and adverse-event narrative; table transcription caveats explicit.
MeasureResultComparison, timing and statistics
Total Symptom Score: end-to-baseline change−5.5 ± 2.6 versus −4.7 ± 2.9; adjusted difference −0.86Actovegin versus placebo · End of study · 95% CI −1.22 to −0.50; p<0.0001
Time-averaged vibration thresholdRatio 0.97Actovegin versus placebo · During treatment · 95% CI 0.94–1.00; p=0.084
Lower-limb neuropathy scoreAdjusted difference −0.48Actovegin versus placebo · End-of-study change · Table 5: p=0.080; CI −1.01 to 0.06. A later table inconsistently prints p=0.008.
Reported adverse events186 active versus 198 placebo events; serious events 10 in 7 active patients versus 11 in 10 placebo patientsEvent counts are not numbers of affected patients

Patent tables contain OCR/sign and p-value inconsistencies; the repeated TSS contrast and its interval were cross-checked across tables. Neutral primary/secondary findings are retained and no independent-trial count is added.

Source for these results ↗ · Reviewed 2026-11-06

Population / setting
Patent disclosure of the published Actovegin diabetic-neuropathy program: 569 randomized; treatment/ITT population 281 active and 286 placebo.
Source reviewed
Original patent publication accessed through Google Patents. Claims, selected reported findings and source limitations checked. The results section identifies the examples, tables and any numerical extraction gaps. No complete experimental audit, prosecution review or legal claim construction was performed.
Study limitations
  • Related trial publications and patent descriptions must not be counted as independent clinical replications.
  • Patent tables contain OCR/sign and p-value inconsistencies; the repeated TSS contrast and its interval were cross-checked across tables. Neutral primary/secondary findings are retained and no independent-trial count is added.
  • Patents record claimed inventions and supporting disclosures. Publication or grant does not establish clinical efficacy, safety or marketing approval. Members of one patent family and related journal reports can describe the same experiments.
  • Status labels are Google Patents index snapshots for the displayed publication or application; each record lists the review date. Official registers and every national family member have not been independently checked. These labels do not establish freedom to operate.

Reviewed 2026-11-06.

Read the source ↗

Review of earlier studies · 2022

Actovegin in the management of patients after ischemic stroke: A systematic review.

The review found uncertain benefit and no consistent evidence of improved survival, disability, daily activities or quality of life. It flagged potential harm and called for better trials.

Study notes and original source
2022ReviewEnglish abstract

Actovegin in the management of patients after ischemic stroke: A systematic review.

Deproteinized calf-blood derivative · Journal publication

la Fleur P, Baizhaxynova A, Reynen E, Kaunelis D, Galiyeva D · PloS one

The review found uncertain benefit and no consistent evidence of improved survival, disability, daily activities or quality of life. It flagged potential harm and called for better trials.

Population / setting
Five controlled studies after ischemic stroke; one randomized trial and four observational studies
Source reviewed
Indexed citation and abstract checked; full methods and risk-of-bias appraisal remain incomplete.
Study limitations
  • Heterogeneous evidence precluded meta-analysis. This review includes ARTEMIDA and is not an independent additional trial.

Reviewed 2026-09-30.

Read the source ↗

Randomized study in people · 2017

ARTEMIDA Trial (A Randomized Trial of Efficacy, 12 Months International Double-Blind Actovegin): A Randomized Controlled Trial to Assess the Efficacy of Actovegin in Poststroke Cognitive Impairment.

The trial reported a cognitive-scale benefit at six months. Recurrent ischemic stroke was numerically more frequent with Actovegin, without a statistically significant difference.

ADAS-cog+ change at month 6 · −6.8 Actovegin versus −4.6 placebo

Study notes and original source
2017Randomized trialEnglish abstract

ARTEMIDA Trial (A Randomized Trial of Efficacy, 12 Months International Double-Blind Actovegin): A Randomized Controlled Trial to Assess the Efficacy of Actovegin in Poststroke Cognitive Impairment.

Deproteinized calf-blood derivative · Journal publication

Guekht A, Skoog I, Edmundson S, Zakharov V, Korczyn AD · Stroke

The trial reported a cognitive-scale benefit at six months. Recurrent ischemic stroke was numerically more frequent with Actovegin, without a statistically significant difference.

Results and tables

Reported findings and study design

ARTEMIDA: 503 patients age ≥60, MoCA≤25, randomized within one week of stroke: Actovegin 248 versus placebo 255. Up to twenty IV infusions 2,000 mg/day, then oral 1,200 mg/day for six months; follow-up 12 months.

Population or model 503 patients aged 60 or older after ischemic stroke; ARTEMIDA

Dose, route and schedule

Actovegin: 2,000 mg/day for up to 20 intravenous infusions, followed by 1,200 mg/day orally, for six months of treatment in total. Treatment began within one week of ischemic stroke.

Protocol source ↗ · Indexed publication abstract

Results · Previously retrieved indexed abstract; numerical statements checked against the saved source text
MeasureResultComparison, timing and statistics
ADAS-cog+ change at month 6−6.8 Actovegin versus −4.6 placebo
Estimated treatment difference−2.3 points; 95% CI −3.9 to −0.7p=0.005
Recurrent ischemic strokeMore frequent with Actovegin, not statistically significantEvent counts absent from abstract

Adjusted treatment difference is retained as −2.3 rather than replacing it with subtraction of the rounded means.

Source for these results ↗ · Reviewed 2026-10-29

Population / setting
503 patients aged 60 or older after ischemic stroke; ARTEMIDA
Source reviewed
Indexed citation and abstract checked; full methods and risk-of-bias appraisal remain incomplete.
Study limitations
  • Clinical importance and replication remain unresolved. The safety imbalance cannot establish causation or be dismissed as proof of safety. Disease-specific results do not establish healthy-person enhancement.

Reviewed 2026-09-30.

Read the source ↗

Randomized study in people · 2009

Treatment of symptomatic polyneuropathy with actovegin in type 2 diabetic patients.

Neuropathic symptoms improved versus placebo. The vibration-threshold coprimary analysis over time did not reach statistical significance, although the final-visit comparison did.

TSS exposure-adjusted difference · −0.56 points; 95% CI −0.85 to −0.27 · p=0.0003

Study notes and original source
2009Randomized trialEnglish abstract

Treatment of symptomatic polyneuropathy with actovegin in type 2 diabetic patients.

Deproteinized calf-blood derivative · Journal publication

Ziegler D, Movsesyan L, Mankovsky B, Gurieva I, Abylaiuly Z, Strokov I · Diabetes care

Neuropathic symptoms improved versus placebo. The vibration-threshold coprimary analysis over time did not reach statistical significance, although the final-visit comparison did.

Results and tables

Reported findings and study design

567 diabetic-neuropathy patients: Actovegin 281 versus placebo 286. Twenty IV infusions 2,000 mg/day, then oral 1,800 mg/day for 140 days; total 160 days.

Population or model 567 treated participants with type 2 diabetes and symptomatic polyneuropathy

Dose, route and schedule

Actovegin: 20 intravenous infusions at 2,000 mg/day, followed by oral treatment at 1,800 mg/day for 140 days in diabetic polyneuropathy.

Protocol source ↗ · Indexed publication abstract

Results · Previously retrieved indexed abstract; numerical statements checked against the saved source text
MeasureResultComparison, timing and statistics
TSS exposure-adjusted difference−0.56 points; 95% CI −0.85 to −0.27p=0.0003
TSS baseline-to-day-160 difference−0.86 points; 95% CI −1.22 to −0.50p<0.0001
Vibration threshold, exposure-adjusted3% decrease; 95% CI 0–6%p=0.084
Vibration threshold at day 1605% decrease; 95% CI 1–9%p=0.017
NIS-LL sensory function−0.25; 95% CI −0.46 to −0.04p=0.021
Adverse-event incidenceNo between-group difference reported

The nonsignificant exposure-adjusted vibration endpoint is preserved alongside the significant end-of-study result.

Source for these results ↗ · Reviewed 2026-10-29

Population / setting
567 treated participants with type 2 diabetes and symptomatic polyneuropathy
Source reviewed
Indexed citation and abstract checked; full methods and risk-of-bias appraisal remain incomplete.
Study limitations
  • Endpoint timing matters; these findings do not establish general nerve regeneration or benefit in healthy people. No difference in adverse-event incidence was reported during this trial.

Reviewed 2026-09-30.

Read the source ↗

Research collection curated by @PepMariner · editorial standards. Send a source correction ↗

Browse bibliography & PDFs ↗